Long-term side effects key when cancer patients choose drugs

June 2, 2012
Long-Term side effects key when cancer patients choose drugs
In 5-month study of people with kidney cancer, one medicine was strongly preferred.

(HealthDay) -- Long-term medication side effects such as fatigue can be key for patients deciding which cancer drug to take, new research suggests.

In the study, people with advanced preferred pazopanib (Votrient) over sunitinib (Sutent), according to a funded by the makers of .

Although doctors may not see a big difference between the two U.S. Food and Drug Administration-approved drugs for the long-term treatment of kidney cancer that has metastasized (spread to other organs), researchers from France found that patients felt Votrient left them less fatigued and with a better , according to the study.

"While we expected patients would prefer one drug over the other, due to the known toxicity profiles, we didn't expect this great a preference," lead study author Dr. Bernard Escudier, a physician at the Institut Gustave Roussy, said in a news release. "This is an excellent method to report the way patients are feeling about the toxicity of drugs. It's an important reminder that low-grade toxicities patients experience may not seem bad, but if you are experiencing the toxicity over a long time, it has an effect on your quality of life."

Typically, reports of associated with drugs don't include how patients feel overall when they take a drug over many months, he added.

In the study, researchers randomly assigned 168 patients with metastatic kidney cancer to receive either Votrient or Sutent for 10 weeks. After a two-week break, the were reversed for another 10 weeks. Neither patients nor physicians knew who was getting which drug.

About 70 percent of patients preferred Votrient, while 22 percent of patients chose Sutent and 8 percent had no preference.

About 60 percent of physicians preferred Votrient, while 21 percent opted for Sutent and 21 percent had no preference. Researchers said that physicians may not be placing as much significance on quality of life differences between the two drugs.

GlaxoSmithKline, the company that makes Votrient, funded the study, which was expected to be presented Saturday at the American Society of Clinical Oncology annual meeting, in Chicago.

Pfizer, the maker of Sutent, issued a statement on the findings on Friday.

"It is important to consider the limitations of this trial design," the drug maker said. The study involved a "small randomized phase 2 trial [and] was based on patient perceived tolerability without complete evaluation of efficacy, a key consideration in the treatment of metastatic cancer patients. Therefore, one cannot establish a full understanding of the comparative risk/benefit profile of SutentR (sunitinib malate) from this study," Pfizer said.

The company also noted that, "through experience in clinical practice and trials, physicians are continuously learning how to optimize the treatment of advanced [kidney cancer] to improve the management of this devastating disease and ensure patients continue to get maximum benefit from ."

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

Explore further: FDA panel backs Pfizer drug for kidney cancer

More information: The U.S. National Cancer Institute provides more information on kidney cancer.

Related Stories

FDA panel backs Pfizer drug for kidney cancer

December 7, 2011
(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

Three 'targeted' cancer drugs raise risk of fatal side effects

February 6, 2012
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...

FDA clears Pfizer drug for advanced kidney cancer

January 27, 2012
(AP) -- The Food and Drug Administration has approved a new Pfizer drug for patients with advanced kidney cancer that has spread to other parts of the body despite treatment with at least one previous drug.

FDA panel backs Glaxo drug for rare sarcoma cancer

March 20, 2012
(AP) -- A panel of cancer experts overwhelmingly backed the approval of a GlaxoSmithKline drug for a rare type of tumor, noting there are few other treatment options for patients.

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.